A team from Brigham and Women’s Hospital in Boston recently published a secondary research analysis indicating that vitamin D supplementation was associated with an overall 17% risk reduction for advanced (metastatic or fatal) cancer.
The new analysis of the Vitamin D and Omega-3 Trial (VITAL) was published in November 2020 in
JAMA Network Open.
1 Findings from the VITAL trial, which concluded in 2018, showed that vitamin D did not reduce overall cancer incidence; however, data hinted at a possible link to a reduction in cancer deaths. In this follow-up analysis, researchers also assessed participants with a normal body mass index (BMI) and found a 38% risk reduction in advanced cancers; this indicated that body mass may be tied to the relationship between vitamin D and the decreased risk. Read more
here.